SOURCE: Medistem Inc

Medistem Inc

September 19, 2011 19:54 ET

Medistem to Present Patient Safety Data on Endometrial Regenerative Cell Product for Treatment of Heart Failure

SAN DIEGO, CA--(Marketwire - Sep 19, 2011) - Medistem Inc. (PINKSHEETS: MEDS) announced it will be presenting results from cardiac patients treated with the company's Endometrial Regenerative Cell (ERC) universal donor stem cell product at the upcoming World Stem Cell Summit Oct 3-4 in Pasadena, California.

"These new data, along with our previous publication describing use of ERC in heart failure (link to paper: http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf), provide support for developing heart failure as Medistem's second clinical indication after critical limb ischemia," said Dr. Vladimir Bogin, Chairman of Medistem Inc. "In the USA heart failure causes approximately 200,000 deaths per year and costs our Health Care system approximately $30 billion per year. It is our intention to expand the current studies to assess whether our 'off the shelf' stem cell product help patients with this devastating condition."

The Endometrial Regenerative Cells (ERC) were discovered by Medistem Inc in 2007 and published in the peer-reviewed literature to be capable of generating 9 different types of tissues include: heart, brain, lung, blood vessel, pancreatic islets, liver, muscle, fat, and bone (link to publication: http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf). Subsequent to Medistem's discovery, numerous groups have reported that cells described in Medistem's ERC intellectual property are capable of treating animal models of heart failure, Parkinson's, diabetes, and stroke.

"The Endometrial Regenerative Cell is different from other stem cell therapies since it is derived from a unique source that naturally is associated with production of new blood vessels," said Thomas Ichim, CEO of Medistem. "Every month the endometrium develops extremely high numbers of new blood vessels, which are subsequently sloughed off in the process of menstruation. We believe the natural function of the ERC is to coordinate production of new blood vessels. Our studies show that these cells can be expanded outside of the body and implanted in other areas of the body to stimulate new blood vessel production. In the case of heart failure, we see these cells as a 'biological bypass.'"

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Thomas Ichim
    Chief Executive Officer
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego, CA 92122
    858 349 3617
    www.medisteminc.com
    twitter: @thomasichim

Webosphere

Keyword Cloud

View Website